放射免疫療法の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR4911)
◆英語タイトル:Global Radioimmunotherapy Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR4911
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:95
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥526,500見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥789,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、放射免疫療法の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(非ホジキンリンパ腫(NHL)、濾胞性リンパ腫、固形腫瘍、乳がん、卵巣がん、骨肉腫、神経芽細胞腫、前立腺がん)、用途別市場規模(腫瘍抗原、放射性核種、抗体)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・放射免疫療法の市場動向
・企業の競争状況、市場シェア
・放射免疫療法の種類別市場規模(非ホジキンリンパ腫(NHL)、濾胞性リンパ腫、固形腫瘍、乳がん、卵巣がん、骨肉腫、神経芽細胞腫、前立腺がん)
・放射免疫療法の用途別市場規模(腫瘍抗原、放射性核種、抗体)
・放射免疫療法の北米市場規模2016-2027(アメリカ、カナダ)
・放射免疫療法の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・放射免疫療法のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・放射免疫療法の中南米市場規模2016-2027(メキシコ、ブラジル)
・放射免疫療法の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Bayer Healthcare Pharmaceuticals、BioSynthema、Clarity Pharmaceuticals、Curasight、Endocyte、Immunomedics、Molecular Insight Pharmaceuticals、Nordic Nanovector、PDL Biopharma、Philogen、RadioMedix、Stella Pharma、Telix Pharmaceuticals)
・結論
【レポートの概要】

Market Analysis and Insights: Global Radioimmunotherapy Market
The global Radioimmunotherapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Radioimmunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Radioimmunotherapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Radioimmunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Radioimmunotherapy market.

Global Radioimmunotherapy Scope and Market Size
Radioimmunotherapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Radioimmunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
Solid Tumors
Breast Cancer
Ovarian Cancer
Osteosarcoma
Neuroblastoma
Prostate Cancer

Segment by Application
Tumor Antigens
Radionuclides
Antibodies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer Healthcare Pharmaceuticals
BioSynthema
Clarity Pharmaceuticals
Curasight
Endocyte
Immunomedics
Molecular Insight Pharmaceuticals
Nordic Nanovector
PDL Biopharma
Curasight
Endocyte

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Non Hodgkin Lymphoma (NHL)
1.2.3 Follicular Lymphoma
1.2.4 Solid Tumors
1.2.5 Breast Cancer
1.2.6 Ovarian Cancer
1.2.7 Osteosarcoma
1.2.8 Neuroblastoma
1.2.9 Prostate Cancer
1.3 Market by Application
1.3.1 Global Radioimmunotherapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Tumor Antigens
1.3.3 Radionuclides
1.3.4 Antibodies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Radioimmunotherapy Market Perspective (2016-2027)
2.2 Radioimmunotherapy Growth Trends by Regions
2.2.1 Radioimmunotherapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Radioimmunotherapy Historic Market Share by Regions (2016-2021)
2.2.3 Radioimmunotherapy Forecasted Market Size by Regions (2022-2027)
2.3 Radioimmunotherapy Industry Dynamic
2.3.1 Radioimmunotherapy Market Trends
2.3.2 Radioimmunotherapy Market Drivers
2.3.3 Radioimmunotherapy Market Challenges
2.3.4 Radioimmunotherapy Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Radioimmunotherapy Players by Revenue
3.1.1 Global Top Radioimmunotherapy Players by Revenue (2016-2021)
3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2016-2021)
3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Radioimmunotherapy Revenue
3.4 Global Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2020
3.5 Radioimmunotherapy Key Players Head office and Area Served
3.6 Key Players Radioimmunotherapy Product Solution and Service
3.7 Date of Enter into Radioimmunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Radioimmunotherapy Breakdown Data by Type
4.1 Global Radioimmunotherapy Historic Market Size by Type (2016-2021)
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2022-2027)

5 Radioimmunotherapy Breakdown Data by Application
5.1 Global Radioimmunotherapy Historic Market Size by Application (2016-2021)
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Radioimmunotherapy Market Size (2016-2027)
6.2 North America Radioimmunotherapy Market Size by Type
6.2.1 North America Radioimmunotherapy Market Size by Type (2016-2021)
6.2.2 North America Radioimmunotherapy Market Size by Type (2022-2027)
6.2.3 North America Radioimmunotherapy Market Size by Type (2016-2027)
6.3 North America Radioimmunotherapy Market Size by Application
6.3.1 North America Radioimmunotherapy Market Size by Application (2016-2021)
6.3.2 North America Radioimmunotherapy Market Size by Application (2022-2027)
6.3.3 North America Radioimmunotherapy Market Size by Application (2016-2027)
6.4 North America Radioimmunotherapy Market Size by Country
6.4.1 North America Radioimmunotherapy Market Size by Country (2016-2021)
6.4.2 North America Radioimmunotherapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Radioimmunotherapy Market Size (2016-2027)
7.2 Europe Radioimmunotherapy Market Size by Type
7.2.1 Europe Radioimmunotherapy Market Size by Type (2016-2021)
7.2.2 Europe Radioimmunotherapy Market Size by Type (2022-2027)
7.2.3 Europe Radioimmunotherapy Market Size by Type (2016-2027)
7.3 Europe Radioimmunotherapy Market Size by Application
7.3.1 Europe Radioimmunotherapy Market Size by Application (2016-2021)
7.3.2 Europe Radioimmunotherapy Market Size by Application (2022-2027)
7.3.3 Europe Radioimmunotherapy Market Size by Application (2016-2027)
7.4 Europe Radioimmunotherapy Market Size by Country
7.4.1 Europe Radioimmunotherapy Market Size by Country (2016-2021)
7.4.2 Europe Radioimmunotherapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Radioimmunotherapy Market Size (2016-2027)
8.2 Asia-Pacific Radioimmunotherapy Market Size by Type
8.2.1 Asia-Pacific Radioimmunotherapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Radioimmunotherapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Radioimmunotherapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Radioimmunotherapy Market Size by Application
8.3.1 Asia-Pacific Radioimmunotherapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Radioimmunotherapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Radioimmunotherapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Radioimmunotherapy Market Size by Region
8.4.1 Asia-Pacific Radioimmunotherapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Radioimmunotherapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Radioimmunotherapy Market Size (2016-2027)
9.2 Latin America Radioimmunotherapy Market Size by Type
9.2.1 Latin America Radioimmunotherapy Market Size by Type (2016-2021)
9.2.2 Latin America Radioimmunotherapy Market Size by Type (2022-2027)
9.2.3 Latin America Radioimmunotherapy Market Size by Type (2016-2027)
9.3 Latin America Radioimmunotherapy Market Size by Application
9.3.1 Latin America Radioimmunotherapy Market Size by Application (2016-2021)
9.3.2 Latin America Radioimmunotherapy Market Size by Application (2022-2027)
9.3.3 Latin America Radioimmunotherapy Market Size by Application (2016-2027)
9.4 Latin America Radioimmunotherapy Market Size by Country
9.4.1 Latin America Radioimmunotherapy Market Size by Country (2016-2021)
9.4.2 Latin America Radioimmunotherapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Radioimmunotherapy Market Size (2016-2027)
10.2 Middle East & Africa Radioimmunotherapy Market Size by Type
10.2.1 Middle East & Africa Radioimmunotherapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Radioimmunotherapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Radioimmunotherapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Radioimmunotherapy Market Size by Application
10.3.1 Middle East & Africa Radioimmunotherapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Radioimmunotherapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Radioimmunotherapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Radioimmunotherapy Market Size by Country
10.4.1 Middle East & Africa Radioimmunotherapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Radioimmunotherapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bayer Healthcare Pharmaceuticals
11.1.1 Bayer Healthcare Pharmaceuticals Company Details
11.1.2 Bayer Healthcare Pharmaceuticals Business Overview
11.1.3 Bayer Healthcare Pharmaceuticals Radioimmunotherapy Introduction
11.1.4 Bayer Healthcare Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.1.5 Bayer Healthcare Pharmaceuticals Recent Development
11.2 BioSynthema
11.2.1 BioSynthema Company Details
11.2.2 BioSynthema Business Overview
11.2.3 BioSynthema Radioimmunotherapy Introduction
11.2.4 BioSynthema Revenue in Radioimmunotherapy Business (2016-2021)
11.2.5 BioSynthema Recent Development
11.3 Clarity Pharmaceuticals
11.3.1 Clarity Pharmaceuticals Company Details
11.3.2 Clarity Pharmaceuticals Business Overview
11.3.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
11.3.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.3.5 Clarity Pharmaceuticals Recent Development
11.4 Curasight
11.4.1 Curasight Company Details
11.4.2 Curasight Business Overview
11.4.3 Curasight Radioimmunotherapy Introduction
11.4.4 Curasight Revenue in Radioimmunotherapy Business (2016-2021)
11.4.5 Curasight Recent Development
11.5 Endocyte
11.5.1 Endocyte Company Details
11.5.2 Endocyte Business Overview
11.5.3 Endocyte Radioimmunotherapy Introduction
11.5.4 Endocyte Revenue in Radioimmunotherapy Business (2016-2021)
11.5.5 Endocyte Recent Development
11.6 Immunomedics
11.6.1 Immunomedics Company Details
11.6.2 Immunomedics Business Overview
11.6.3 Immunomedics Radioimmunotherapy Introduction
11.6.4 Immunomedics Revenue in Radioimmunotherapy Business (2016-2021)
11.6.5 Immunomedics Recent Development
11.7 Molecular Insight Pharmaceuticals
11.7.1 Molecular Insight Pharmaceuticals Company Details
11.7.2 Molecular Insight Pharmaceuticals Business Overview
11.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Introduction
11.7.4 Molecular Insight Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.7.5 Molecular Insight Pharmaceuticals Recent Development
11.8 Nordic Nanovector
11.8.1 Nordic Nanovector Company Details
11.8.2 Nordic Nanovector Business Overview
11.8.3 Nordic Nanovector Radioimmunotherapy Introduction
11.8.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2016-2021)
11.8.5 Nordic Nanovector Recent Development
11.9 PDL Biopharma
11.9.1 PDL Biopharma Company Details
11.9.2 PDL Biopharma Business Overview
11.9.3 PDL Biopharma Radioimmunotherapy Introduction
11.9.4 PDL Biopharma Revenue in Radioimmunotherapy Business (2016-2021)
11.9.5 PDL Biopharma Recent Development
11.10 Philogen
11.10.1 Philogen Company Details
11.10.2 Philogen Business Overview
11.10.3 Philogen Radioimmunotherapy Introduction
11.10.4 Philogen Revenue in Radioimmunotherapy Business (2016-2021)
11.10.5 Philogen Recent Development
11.11 RadioMedix
11.11.1 RadioMedix Company Details
11.11.2 RadioMedix Business Overview
11.11.3 RadioMedix Radioimmunotherapy Introduction
11.11.4 RadioMedix Revenue in Radioimmunotherapy Business (2016-2021)
11.11.5 RadioMedix Recent Development
11.12 Stella Pharma
11.12.1 Stella Pharma Company Details
11.12.2 Stella Pharma Business Overview
11.12.3 Stella Pharma Radioimmunotherapy Introduction
11.12.4 Stella Pharma Revenue in Radioimmunotherapy Business (2016-2021)
11.12.5 Stella Pharma Recent Development
11.13 Telix Pharmaceuticals
11.13.1 Telix Pharmaceuticals Company Details
11.13.2 Telix Pharmaceuticals Business Overview
11.13.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
11.13.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2016-2021)
11.13.5 Telix Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 放射免疫療法の世界市場規模・現状・予測2021年-2027年(Global Radioimmunotherapy Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。